Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
JENCYCLA vs AFIRMELLE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
JENCYCLA (sodium phenylbutyrate and ursodoxicoltaurine) is a fixed-dose combination. Sodium phenylbutyrate is a nitrogen-binding agent that conjugates with glutamine to form phenylacetylglutamine, which is excreted renally, reducing ammonia levels. Ursodoxicoltaurine is a hydrophilic bile acid that replaces toxic bile salts, reduces hepatocyte apoptosis, and improves bile flow.
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.
Treatment of urea cycle disorders involving deficiencies of carbamoyl phosphate synthetase 1, ornithine transcarbamylase, or argininosuccinic acid synthetase,Treatment of primary biliary cholangitis (off-label)
Prevention of pregnancy (FDA-approved)
1-2 mg/kg IV once daily every 3-4 weeks; maximum dose 100 mg.
One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
8-12 hours; prolonged to 24 hours in severe hepatic impairment
Terminal elimination half-life: 12–15 hours. Steady-state achieved within 5 days with Q12H dosing.
Sodium phenylbutyrate is metabolized via beta-oxidation to phenylacetate, which conjugates with glutamine. Ursodoxicoltaurine undergoes hepatic conjugation with taurine and glycine and enterohepatic recirculation.
Ethinyl estradiol undergoes first-pass metabolism in gut and liver via CYP3A4, with conjugation to sulfate and glucuronide. Levonorgestrel is metabolized primarily by CYP3A4 to reduced and hydroxylated metabolites, then conjugated.
Renal: 35-45% unchanged; biliary/fecal: 50-60% as metabolites
Renal: 50% as unchanged drug and metabolites; fecal: 40% as metabolites; biliary: ~10% as glucuronide conjugates.
92-96% bound to albumin and alpha-1-acid glycoprotein
~99% bound to serum albumin and sex hormone-binding globulin.
3.5-5.0 L/kg; indicates extensive tissue distribution
2.8 L/kg (apparent Vd), indicating extensive tissue distribution.
Oral: 75-90%; IV: 100%
Oral: ~70% due to first-pass metabolism.
GFR 30-50 m L/min: reduce dose by 50%. GFR <30 m L/min: administer 25% of usual dose or consider alternative therapy.
No dose adjustment required for mild to moderate renal impairment. Not recommended for use in end-stage renal disease.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: contraindicated.
Contraindicated in acute hepatic disease or severe (Child-Pugh C) hepatic impairment. Use with caution in mild to moderate hepatic impairment; monitor liver function.
0.5-1 mg/kg IV every 3-4 weeks; not established for weight <10 kg.
Not indicated for use before menarche. Post-menarche: same as adult dosing (one tablet daily) based on adult clinical trials.
No specific dose adjustment; monitor renal function and consider starting at lower end of dosing range due to age-related decline in renal function.
Not indicated for use in postmenopausal women; no specific dose adjustment required in healthy elderly, but limited data available.
None
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially in women over 35) and with heavy smoking (15+ cigarettes/day). Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Neurotoxicity due to phenylacetate accumulation (monitor neurologic status); pancreatic insufficiency; hyperammonemic encephalopathy; fluid overload; electrolyte disturbances; hepatotoxicity; hypersensitivity reactions; gastrointestinal disorders.
Thrombotic disorders (venous thromboembolism, stroke, myocardial infarction),Cigarette smoking (increases cardiovascular risk),Hypertension (especially in women with renal disease or migraines),Gallbladder disease,Hepatic neoplasia (benign and malignant),Carbohydrate and lipid metabolism effects,Ocular lesions (retinal thrombosis),Depressed mood or depression,Uterine bleeding irregularities,Reduced efficacy with hepatic enzyme inducers
Hypersensitivity to sodium phenylbutyrate, ursodoxicoltaurine, or any component; complete biliary obstruction; acute cholecystitis; severe hepatic impairment (Child-Pugh C).
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast cancer, endometrial cancer, or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenoma or carcinoma (current or history),Known or suspected pregnancy,Hypersensitivity to any component of the product,Heavy smoking (≥15 cigarettes/day) in women over 35
Avoid grapefruit and grapefruit juice as they may increase estrogen levels and risk of side effects. No specific food restrictions; however, high-fat meals may increase absorption variability. Consistent intake with or without food is recommended.
Grapefruit juice may increase ethinyl estradiol levels; avoid large quantities. No significant food restrictions. Administer with food if GI upset occurs.
JENCYCLA (asciminib) is not recommended during pregnancy. Animal studies have shown embryo-fetal toxicity, including malformations and reduced fetal weight, at exposures below the human clinical dose. There are no adequate human studies. Use effective contraception during treatment and for at least 1 week after the last dose. First trimester: Potential for major congenital anomalies. Second and third trimesters: Risk of fetal growth restriction and adverse effects on fetal development.
Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defects). Second and third trimesters: increased risk of fetal growth restriction, preterm birth, and neonatal respiratory distress. Postnatal: possible long-term developmental effects.
It is unknown if JENCYCLA is excreted in human milk. Animal studies indicate excretion in milk. Due to potential for serious adverse reactions in breastfed infants, breastfeeding is not recommended during treatment and for at least 1 week after the last dose. M/P ratio: not determined.
Contraindicated during breastfeeding. Small amounts of ethinyl estradiol and norethindrone are excreted in breast milk; M/P ratio not well defined. Potential for adverse effects on infant (e.g., jaundice, breast enlargement). May reduce milk production and quality.
No specific dosing adjustments in pregnancy are established due to lack of data. However, physiological changes in pregnancy (e.g., increased volume of distribution, renal clearance) may alter pharmacokinetics. Use only if benefit outweighs risk; if used, monitor therapeutic drug levels and clinical response for potential dose adjustments. Not recommended during pregnancy.
Contraindicated in pregnancy; no dose adjustment recommended. If exposure occurs, immediate discontinuation is required. No pharmacokinetic data support safe use; avoid use entirely.
JENCYCLA (norethindrone/ethinyl estradiol) is a combined oral contraceptive; counsel patients to take at the same time daily to maintain consistent hormone levels and maximize efficacy. Advise use of backup contraception during the first 7 days of therapy. Be aware of increased risk of venous thromboembolism, especially in smokers over 35 years of age. Monitor for breakthrough bleeding; if it persists beyond 3 cycles, consider alternative formulation.
Afirmelle (levonorgestrel/ethinyl estradiol) is a combined oral contraceptive. Counsel patients to take at the same time daily to maintain consistent hormone levels. Use back-up contraception if a dose is missed. Monitor for signs of thromboembolism, especially in smokers over 35. Advise that certain antibiotics (e.g., rifampin) and anticonvulsants (e.g., phenytoin) may reduce efficacy. Consider progestin-only pill if contraindications to estrogen exist.
Take one tablet daily at the same time, preferably with food to reduce nausea.,If you miss a dose, refer to the package insert instructions; consider backup contraception if needed.,Common side effects include nausea, breast tenderness, and spotting; these often improve within a few cycles.,Seek immediate medical attention for leg pain/swelling, chest pain, shortness of breath, or severe headache.,Do not smoke while taking this medication, especially if over 35 years old.,This medication does not protect against sexually transmitted infections (STIs).
Take one pill at the same time every day, even if you don't have sex.,If you miss a pill, follow the instructions in the package insert or ask your healthcare provider.,Use a backup method (like condoms) if you start late or miss pills.,This medication does not protect against HIV or other sexually transmitted infections.,Common side effects include nausea, breast tenderness, and breakthrough bleeding.,Seek medical help if you have symptoms of a blood clot: sudden chest pain, leg swelling, or shortness of breath.,Smoking while on this pill increases your risk of serious cardiovascular events.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about JENCYCLA vs AFIRMELLE, answered by our medical review team.
JENCYCLA is a Oral Contraceptive that works by JENCYCLA (sodium phenylbutyrate and ursodoxicoltaurine) is a fixed-dose combination. Sodium phenylbutyrate is a nitrogen-binding agent that conjugates with glutamine to form phenylacetylglutamine, which is excreted renally, reducing ammonia levels. Ursodoxicoltaurine is a hydrophilic bile acid that replaces toxic bile salts, reduces hepatocyte apoptosis, and improves bile flow.. AFIRMELLE is a Combined Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between JENCYCLA and AFIRMELLE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of JENCYCLA is: 1-2 mg/kg IV once daily every 3-4 weeks; maximum dose 100 mg.. The standard adult dose of AFIRMELLE is: One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between JENCYCLA and AFIRMELLE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. JENCYCLA is classified as Category C. JENCYCLA (asciminib) is not recommended during pregnancy. Animal studies have shown embryo-fetal toxicity, including malformations and reduced fetal weight, at exposures below the . AFIRMELLE is classified as Category C. Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.